Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Bristol-Myers Squibb (NYSE: BMY), signaling sustained confidence in the pharmaceutical company’s investment potential. This rating reaffirmation suggests that analysts view the stock favorably within its current market context.

Analyst Action

The decision to maintain the Buy stance comes from Robyn Karnauskas at Truist Securities. The firm continues to recommend holding or acquiring shares of Bristol-Myers Squibb for investors aligned with this growth outlook.

Key Details

This rating update reflects the firm’s ongoing assessment of Bristol-Myers Squibb’s performance and future prospects in the healthcare sector.

Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter adjusted earnings of $2.04 per share, surpassing the Wall Street estimate of $1.59, and raised its full-year fiscal 2026 guidance on robust performance from its growth portfolio. The pharmaceutical giant posted quarterly revenue of $12.973 billion, a 6% increase that exceeded the consensus estimate of $11.745 billion, driven by double-digit growth in key products such as Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag.

Christopher Boerner, board chair and CEO of Bristol-Myers Squibb, attributed the positive results to consistent execution and a differentiated pipeline designed to generate long-term value. Consequently, the company increased its fiscal 2026 adjusted earnings guidance from $6.05-$6.35 per share to $6.75-$7 per share, beating the consensus of $6.34 per share. Additionally, Bristol-Myers Squibb raised its fiscal 2026 sales guidance from $46 billion-$47.50 billion to $49 billion-$50 billion, compared to the consensus of $47.472 billion.

Portfolio Performance Breakdown

The company’s Growth Portfolio generated revenues of $7.6 billion, representing a 15% increase (14% on a constant currency basis). This segment was primarily propelled by newer therapies including Opdivo Qvantig and Reblozyl. In contrast, the Legacy Portfolio saw revenues decline by 4% (5% on constant currency) to $5.4 billion. While demand for Eliquis increased significantly, this gain was offset by expected generic impacts across other legacy products.

Outlook and Dividend Implications

Bristol-Myers Squibb expects global Eliquis revenue to grow by 20% to 25% in fiscal 2026. The updated guidance assumes continued strength in the Growth Portfolio alongside a projected 4%-6% decline in the Legacy Portfolio. Shares of Bristol-Myers Squibb rose 2.38% to close at $64.56 following the announcement.

For income-focused investors, the stock’s annual dividend yield stands at approximately 3.96%, with a quarterly payout of $0.63 per share ($2.52 annually). To generate a monthly dividend income of $500 ($6,000 annually), an investor would need to hold approximately 2,381 shares, representing an investment of roughly $151,432 at current prices. A more conservative target of $100 monthly ($1,200 annually) requires holding 476 shares, or about $30,274 worth of stock.

What the Numbers Show

The divergence between the Growth and Legacy portfolios highlights Bristol-Myers Squibb’s successful transition toward newer, higher-margin therapies. While the Legacy Portfolio faces headwinds from generic competition, the 15% surge in Growth Portfolio revenue demonstrates the commercial traction of recent innovations. The significant raise in full-year guidance suggests management confidence in sustaining this momentum, particularly given the projected 20%-25% growth for Eliquis, which remains a critical cash flow generator despite broader legacy declines.